Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4651332 | 0.84 | HSD17B2 (0.66) | CA1CA2CA4CA7CA9 | |
| SCHEMBL12768024 | 0.82 | FFAR4 (0.61) | FFAR4CA1CA2CA4CA7 | |
| SCHEMBL7579899 | 0.81 | CA1 (0.60) | FFAR4CA1CA2CA4CA7 | |
| SCHEMBL4649684 | 0.81 | SLC22A12 (0.54) | FFAR4SLC22A12KMT2A | |
| SCHEMBL22654320 | 0.79 | ALDH1A1 (0.54) | FFAR4CA1CA2CA4CA7 | |
| SCHEMBL30949870 | 0.79 | ALDH1A1 (0.54) | FFAR4CA1CA2CA4CA7 | |
| SCHEMBL29083820 | 0.78 | CA1 (0.50) | FFAR4CA1CA2CA4CA7 | |
| SCHEMBL1626061 | 0.77 | SLC22A12 (0.44) | SLC22A12CA1CA2CA4CA7 | |
| SCHEMBL6553546 | 0.77 | LMNA (0.64) | SLC22A12CA1CA2CA4CA7 | |
| SCHEMBL29083812 | 0.77 | CA2 (0.63) | FFAR4CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2008076918-A9 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIV MARYLAND (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008076918-A2 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | AR, HTR3D, NR5A1 | FFAR4 314/4885SLC22A12 1759/4885CA1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.